Empowered Funds’s Cardlytics CDLX Stock Holding History

Empowered Funds’s Portfolio CDLX Stock Details CDLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-1,778	Closed	-$1.25M	–	171
2020 Q3	$1.25M	Buy	+1,778	New	+$1.29M	0.39%	97

Other funds holding CDLX

CIP

CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

KGAMU

KPS Global Asset Management (UK) London, United Kingdom $620M AUM 14.15% 1-Year Est. Return

ACM

Alua Capital Management New York $1.13B AUM 8.41% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Empowered Funds's CDLX Position: Q4 2020 in Review

Empowered Funds sold out of Cardlytics (CDLX) in Q4 2020, closing a stake of 1,778 shares — an estimated $1.25M sold.

Empowered Funds first reported a position in CDLX in Q3 2020 and held it in 1 quarter. The position peaked at $1.25M in Q3 2020. 195 funds tracked by Wall St. Rank hold CDLX as of Q4 2020.

Empowered Funds reported no remaining Cardlytics position as of Q4 2020 after selling out during the quarter.
Empowered Funds sold 1,778 Cardlytics shares in Q4 2020, an estimated $1.25M.
Empowered Funds first reported a position in Cardlytics in Q3 2020 and held it in 1 quarter.
Empowered Funds's Cardlytics position peaked at $1.25M in Q3 2020.
195 funds tracked by Wall St. Rank held Cardlytics as of Q4 2020.

Based on Empowered Funds's 13F filing for Q4 2020, filed 2 Feb 2021.